COVID-19 IN PRIMARY HEALTHCARE

Gökseven, Yağmur; ACAR, Hüseyin; arıca, seçil; zerenozturk, guzin

doi:10.5505/amj.2020.92679

COVID-19 IN PRIMARY HEALTHCARE

Hüseyin ACAR, (Ümraniye Zeyneloğlu Aile Sağlığı Merkezi, İstanbul, Türkiye)

Yağmur GÖKSEVEN, (Hassa Bölge Hastanesi, Hatay, Türkiye)

Güzin ZERENÖZTÜRK, (Sağlık Bilimleri Üniversitesi, Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi, Aile Sağlık Klinikleri, İstanbul, Türkiye)

Seçil Günher ARICA (Sağlık Bilimleri Üniversitesi, Prof.Dr.Cemil Taşçıoğlu Şehir Hastanesi, Aile Hekimliği Klinikleri, İstanbul, Türkiye)

Ankara Medical Journal

1 0

Yıl: 2020 Cilt: 20 Sayı: 2 Sayfa Aralığı: 444 - 467 Metin Dili: İngilizce DOI: 10.5505/amj.2020.92679 İndeks Tarihi: 05-11-2020

COVID-19 IN PRIMARY HEALTHCARE

Öz:

The coronaviruses are a large family of viruses infecting animals or humans and causing diseases, includingMiddle East Respiratory Syndrome(MERS, MERS-CoV) and Severe Acute Respiratory Syndrome(SARS, SARSCoV). The novel coronavirus SARS-CoV-2 emerged in December 2019 at the city of Wuhan, affecting therespiratory system leading to pneumonia, pulmonary edema, Acute Respiratory Distress Syndrome,multiorgan failure, and death. Treatment studies are still ongoing, but hydroxychloroquine, azithromycin,oseltamivir, favipiravir with some other anti-virals, and convalescent plasma therapy are prominent. Themortality rate of disease is 3.8% in the world, infesting many countries. Legal regulations have been made forthe public to reduce transmission. Family health centers are providing healthcare services to every individual,for example, children, pregnant, patients with chronic diseases, patients with any complaint, and individualswho applied for health papers. In such a pandemic family, physicians also have to restrain the transmission ofviruses between those people who applied. Therefore triage is needed to determine the high-risk patients assoon as possible. Both of them and other patients are protected in that way. After the filiation is done, suspectedcases or COVID-19 contacted cases are kept in touch by family physicians to follow up their clinical status andcheck for isolation conditions. For all these reasons, we aimed to examine the family health centers coping withCOVID-19.

Anahtar Kelime:

BİRİNCİ BASAMAKTA COVID-19

Öz:

Koronavirüsler, hayvanları veya insanları enfekte edebilen ve Orta Doğu Solunum Sendromu (MERS) ve Şiddetli Akut Solunum Sendromu (SARS) gibi hastalıklara neden olan büyük bir virüs ailesidir. Yeni koronavirüs (SARS-CoV-2) Aralık 2019'da Wuhan şehrinde ortaya çıkan ve pnömoni, pulmoner ödem, ARDS, multiorgan yetmezliği ve ölüme sebebiyet verebilen bir solunum yolu enfeksiyon etkenidir. Tedavi çalışmaları devam etmekle birlikte şu an hidroksiklorokin, azitromisin, plazma tedavisi ve favipiravir gibi anti-viraller öne çıkan tedavilerdir. Hastalığın ölüm oranı %3,8'dir. Yayılımın azalmasını sağlamak amacıyla yasal düzenlemeler yapılmıştır. Aile sağlığı merkezleri (ASM) çocuk, gebe, yaşlı, kronik hastalığı olan hastalar ve birtakım sağlık belgeleri için başvuran kişilere hizmet veren birinci basamak sağlık kurumlarıdır. Pandemi varlığında aile hekimleri, ASM’lere başvuran kişiler arasında virüs iletimini kısıtlamak zorundadır. Bu nedenle triaj yapılması yüksek riskli hastaları mümkün olan en kısa sürede saptamak için gereklidir. ASM’lere başvuran tüm hastalar bu şekilde korunabilir. Filyasyon yapıldıktan sonra, şüpheli vakalar veya COVID-19 ile temas eden vakalar aile hekimleri tarafından klinik durumlarının takip edilmesi ve izolasyon koşullarının kontrol edilmesi amacıyla günlük olarak takip edilmektedir. Tüm bu nedenlerden ötürü, COVID-19 ile mücadele eden aile sağlığı merkezlerini incelemeyi amaçladık.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. World Health Organisation Department of Communicable Disease Surveillance and Response. WHO guidelines for the global surveillance of severe acute respiratory syndrome ( SARS ) 2004. [Internet]. https://www.who.int/csr/resources/publications/WHO_CDS_CSR_ARO_2004_1.pdf (Access Date: 04.04.2020)
2. Sampathkumar, Priya Temesgen Z, Smith TF, Thompson RL. SARS: Epidemiology, Clinical Presentation, Management, and Infection Control Measures. Mayo Clin Proc 2003;78:882 –90.
3. World Health Organisation. Middle East respiratory syndrome coronavirus (MERS-CoV) 2019 [Internet]. https://www.who.int/en/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus- (mers-cov) (Access Date: 06.04.2020)
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
5. World Health Organisation. Laboratory testing for coronavirus disease ( COVID-19 ) in suspected human cases. 2020. [Internet]. https://apps.who.int/iris/bitstream/handle/10665/331501/WHO-COVID-19- laboratory-2020.5-eng.pdf (Access Date: 31.03.2020)
6. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395:514–23.
7. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565–74.
8. Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med 2020;382(1):1564–7.
9. Aylward, Bruce (WHO); Liang W (PRC). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 2020. [Internet]. http://www.who.int/docs/default-source/coronaviruse/who-chinajoint-mission-on-covid-19-final-report.pdf (Access Date: 06.04.2020)
10. Burke RM, Midgley CM, Dratch A, Fenstersheib M, Haupt T, Holshue M, et al. Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 - United States, January-February 2020. Morb Mortal Wkly Rep 2020;69(9):245–6.
11. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2. Morb Mortal Wkly Rep 2020;69(14):411–5.
12. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020;395(10223):470–3.
13. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
14. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. J Am Med Assoc 2020;323(11):1061 –9.
15. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. J Infect 2020;80(4):401–6. (doi:10.1016/j.jinf)
16. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New Engl J Med J Med Orig 2020;1–13. (doi:10.1056/NEJMoa2002032)
17. Cao Y, Liu X, Xiong L, Cai K. Imaging and Clinical Features of Patients With 2019 Novel Coronavirus SARS-CoV-2: A systematic review and meta-analysis. J Med Virol 2020;(March):1–11.
18. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. Journal of the American Medical Association. 2020;19–20. (doi:10.1001/jama.2020.3786)
19. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020;March. (doi:10.1093/cid/ciaa344)
20. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. COVID-19 Rehberi 2020. [Internet]. https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf (Access Date: 18.04.2020)
21. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med 2020. (doi:10.7326/M20-0504)
22. Yoon SH, Lee KH, Kim JY, Lee YK, Ko H, Kim KH, et al. Chest radiographic and ct findings of the 2019 novel coronavirus disease (Covid-19): Analysis of nine patients treated in korea. Korean J Radiol 2020;21(4):498–504.
23. Lee EYP, Ng MY, Khong PL. COVID-19 pneumonia: what has CT taught us? Lancet Infect Dis 2020;20(4). 384–5.
24. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. RSNA - Radiol 2020 (doi:10.1148/radiol.2020200642)
25. Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020;177:104762. (doi:10.1016/j.antiviral.2020.104762.)
26. Ahn D, Shin H, Kim M-H, Lee S, Kim H-S, Myoung J, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol 2020;30(3):313–24.
27. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30(3):269–71.
28. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment o f COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14(1):1–2.
29. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. (doi:10.1093/cid/ciaa237)
30. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. Drug Safety 2018;41:919–31.
31. Aktoz M, Altay H, Aslanger E, Atalar E, Aytekin V, Baykan AO, et al. Consensus Report from Turkish Society of Cardiology: COVID-19 and Cardiovascular Diseases. What cardiologists should know. Arch Turkish Soc Cardiol 2020;48(0):1–48. (doi:10.5543/tkda.2020.97198)
32. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet 2020;20:398–9.
33. Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv 2020. (doi:10.1101/2020.02.05.935387)
34. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.
35. Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. J Chem Inf Model 2012;53(9):1689–99.
36. Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report. Int J Infect Dis 2020;93:297–9.
37. Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020;(February):4– 7.(doi:10.1093/jac/dkaa114/5810487)
38. Agrawal S, Goel AD, Gupta N. Emerging prophylaxis strategies against COVID-19. Monaldi Arch Chest Dis 2020;90(1):169–72.
39. Indian Council of Medical Research. Advisory on the use of Hydroxychloroquin as prophylaxis for SARS CoV2 infection. 2020. [Internet]. https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infe ction.pdf (Access Date: 24.03.2020)
40. World Health Organisation. Coronavirus disease (COVID-19) advice for the public: Myth busters. 2020. [Internet]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-forpublic/myth-busters (Access Date: 01.04.2020)
41. World Health Organisation. Coronavirus disease (COVID-19) advice for the public: When and how to use masks. 2020. [Internet]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advicefor-public/when-and-how-to-use-masks (Access Date: 08.04.2020)
42. T.C. İçişleri Bakanlığı. Şehir Giriş/Çıkış Tebirleri ve Yaş Sınırlaması Genelgesi Turkiye; 2020. [Internet]. Available from: https://www.icisleri.gov.tr/sehir-giriscikis-tebirleri-ve-yas-sinirlamasi (Access Date: 22.04.2020)
43. Klompas M, Morris CA, Sinclair J, Pearson M, Shenoy ES. Universal Masking in Hospitals in the Covid-19 Era. N Engl J Med 2020;382:1476–78. (doi:10.1056/NEJMp2006372)
44. American Academy of Family Physicians. COVID-19: Guidance for Family Physicians on Preventive and Non-Urgent Care. 2020.
45. T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü. Poliklinik ve Sağlık Raporları Hakkında Alınacak Tedbirler Turkiye; 2020. [Internet]. https://dosyamerkez.saglik.gov.tr/Eklenti/36990,poliklinik-ve-saglikustyazi961f936a-5827-4b02-b5fed0d7c5ca81c1pdf.pdf?0&_tag1=D16155C87DEE76A7E26083D1E8C0AE4754D1502D (Access Date: 22.04.2020)
46. British Columbia Centre for Disease Control. Environmental Cleaning and Disinfectants for Clinic Settings.; 2020. [Internet]. http://www.bccdc.ca/Health-Professionals-Site/Documents/COVID- 19_MOH_BCCDC_EnvironmentalCleaning.pdf (Access Date: 24.04.2020)
47. Health Protection Scotland. Novel coronavirus (COVID-19) Guidance for primary care. 2020. [Internet]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/8 81489/COVID- 19_Infection_prevention_and_control_guidance_complete.pdf (Access Date: 26.04.2020)
48. European Centre for Disease Prevention and Control. Safe use of personal protective equipment in the treatment of infectious diseases of high consequence: A tutorial for trainers in healthcare settings. 2014. [Internet]. https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/safeuse-of-ppe.pdf (Access Date: 18.04.2020)
49. Centers for Disease Control and Prevention. Jong, de F. Infographic- Understanding the Diffirence, Surgical Mask, N95 Respirator 2018. [Internet]. https://www.cdc.gov/niosh/npptl/pdfs/UnderstandDifferenceInfographic-508.pdf (Access Date: 10.04.2020)
50. Stanford Medicine. Price A, Chu L. What are good ways to address the shortage of face masks by anesthesiologists ? 2020. [Internet]. https://stanfordmedicine.app.box.com/v/covid19-PPE-1-1 (Access Date: 03.04.2020)
51. Tsai P. Information and FAQs on the Performance, Protection, and Sterilization of Face Mask Materials. 2020. [Internet]. Available from: https://utrf.tennessee.edu/information-faqs-performance-protectionsterilization-of-face-mask-materials/ (Access Date: 04.04.2020)
52. Türk Tabipler Birliği. Sağlık çalışanında Covid-19 tanısı iş kazası veya meslek hastalığıdır [Internet]. https://www.ttb.org.tr/haber_goster.php?Guid=92238894-726a-11ea-b12d-d839943d748d (Access Date: 10.04.2020)
53. World Health Organisation. Rational use of personal protective equipment for coronavirus disease 2019 ( COVID-19 ). 2020. [Internet]. https://www.who.int/publications-detail/rational-use-of-personalprotective-equipment-for-coronavirus-disease-(covid-19)-and-considerations-during-severe-shortages (Access Date: 14.04.2020)
54. Goodwin Veenema T. Sequence for Putting on Personal Protective Equipment. In: Disaster Nursing and Emergency Preparedness 2018. p. 682–4. [Internet]. https://www.cdc.gov/hai/pdfs/ppe/ppesequence.pdf (Access Date: 10.04.2020)
55. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Bulaşıcı Hastalıklarla Mücadele Rehberi Turkiye; 2018. [Internet]. https://hsgm.saglik.gov.tr/depo/mevzuat/genelge/Bulasici_Hastaliklar_ile_Mucadele_Rehberi_Ustyazi.p df (Access Date: 22.04.2020)
56. European Center for Disease Prevention and Control. Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – seventh update. 2020; [Internet] . https://www.ecdc.europa.eu/sites/default/files/documents/RRA-seventh-update-Outbreak-ofcoronavirus-disease-COVID-19.pdf (Access Date: 28.03.2020)
57. Ontorio College of Family Physicians. Tips for family doctors. 2020 [Internet]. https://www.ontariofamilyphysicians.ca/tools-resources/timely-trending/novel-coronavirus-2019- ncov/novel-coronavirus:-tips-for-family-doctors (Access Date: 02.04.2020)

APA	ACAR H, Gökseven Y, zerenozturk g, arıca s (2020). COVID-19 IN PRIMARY HEALTHCARE. , 444 - 467. 10.5505/amj.2020.92679
Chicago	ACAR Hüseyin,Gökseven Yağmur,zerenozturk guzin,arıca seçil COVID-19 IN PRIMARY HEALTHCARE. (2020): 444 - 467. 10.5505/amj.2020.92679
MLA	ACAR Hüseyin,Gökseven Yağmur,zerenozturk guzin,arıca seçil COVID-19 IN PRIMARY HEALTHCARE. , 2020, ss.444 - 467. 10.5505/amj.2020.92679
AMA	ACAR H,Gökseven Y,zerenozturk g,arıca s COVID-19 IN PRIMARY HEALTHCARE. . 2020; 444 - 467. 10.5505/amj.2020.92679
Vancouver	ACAR H,Gökseven Y,zerenozturk g,arıca s COVID-19 IN PRIMARY HEALTHCARE. . 2020; 444 - 467. 10.5505/amj.2020.92679
IEEE	ACAR H,Gökseven Y,zerenozturk g,arıca s "COVID-19 IN PRIMARY HEALTHCARE." , ss.444 - 467, 2020. 10.5505/amj.2020.92679
ISNAD	ACAR, Hüseyin vd. "COVID-19 IN PRIMARY HEALTHCARE". (2020), 444-467. https://doi.org/10.5505/amj.2020.92679

APA	ACAR H, Gökseven Y, zerenozturk g, arıca s (2020). COVID-19 IN PRIMARY HEALTHCARE. Ankara Medical Journal, 20(2), 444 - 467. 10.5505/amj.2020.92679
Chicago	ACAR Hüseyin,Gökseven Yağmur,zerenozturk guzin,arıca seçil COVID-19 IN PRIMARY HEALTHCARE. Ankara Medical Journal 20, no.2 (2020): 444 - 467. 10.5505/amj.2020.92679
MLA	ACAR Hüseyin,Gökseven Yağmur,zerenozturk guzin,arıca seçil COVID-19 IN PRIMARY HEALTHCARE. Ankara Medical Journal, vol.20, no.2, 2020, ss.444 - 467. 10.5505/amj.2020.92679
AMA	ACAR H,Gökseven Y,zerenozturk g,arıca s COVID-19 IN PRIMARY HEALTHCARE. Ankara Medical Journal. 2020; 20(2): 444 - 467. 10.5505/amj.2020.92679
Vancouver	ACAR H,Gökseven Y,zerenozturk g,arıca s COVID-19 IN PRIMARY HEALTHCARE. Ankara Medical Journal. 2020; 20(2): 444 - 467. 10.5505/amj.2020.92679
IEEE	ACAR H,Gökseven Y,zerenozturk g,arıca s "COVID-19 IN PRIMARY HEALTHCARE." Ankara Medical Journal, 20, ss.444 - 467, 2020. 10.5505/amj.2020.92679
ISNAD	ACAR, Hüseyin vd. "COVID-19 IN PRIMARY HEALTHCARE". Ankara Medical Journal 20/2 (2020), 444-467. https://doi.org/10.5505/amj.2020.92679